The ABL kinase inhibitor STI571 does not affect survival of hematopoietic cells after ionizing radiation

被引：0
|
作者：
Uemura, N [1 ]
Griffin, JD [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2000年 / 96卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3294 / 3295
页数：2
相关论文
共 50 条
  • [21] The tyrosine kinase inhibitor STI571 prolongs survival in a murine model of chronic myelogenous leukemia.
    Wolff, NC
    Xu, HM
    Zhang, SM
    Ilaria, RL
    BLOOD, 2000, 96 (11) : 344A - 344A
  • [22] Regulation of cardiovascular remodeling by STI571, an inhibitor of PDGF receptor tyrosine kinase
    Takeda, N
    Iwata, H
    Niu, P
    Limuro, S
    Shindo, T
    CIRCULATION, 2004, 110 (17) : 115 - 115
  • [23] Effects of the bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on leukemic cells in vitro.
    Chandra, J
    Mow, B
    Weisberg, E
    Griffin, J
    Sausville, EA
    Tefferi, A
    Kaufmann, SH
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3768S - 3769S
  • [24] Amplification of the BCR/ABL gene in transformed hematopoietic cell lines resistant to the ABL tyrosine kinase inhibitor STI571.
    Weisberg, EL
    Griffin, JD
    BLOOD, 1999, 94 (10) : 387A - 387A
  • [25] Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours
    Joensuu, H
    Dimitrijevic, S
    ANNALS OF MEDICINE, 2001, 33 (07) : 451 - 455
  • [26] Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells
    J Topaly
    WJ Zeller
    S Fruehauf
    Leukemia, 2001, 15 : 342 - 347
  • [27] Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571
    Yoshitani, K
    Honoki, K
    Morishita, T
    Kido, A
    Miyauchi, Y
    Mii, Y
    Takakura, Y
    IN VIVO, 2003, 17 (03): : 255 - 258
  • [28] The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells
    Ertmer, A
    Gilch, S
    Yun, SW
    Flechsig, E
    Klebl, B
    Stein-Gerlach, M
    Klein, MA
    Schätzl, HM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (40) : 41918 - 41927
  • [29] Effects of the tyrosine-kinase inhibitor STI571 on mutated KIT and neoplastic mast cells.
    Akin, C
    Longley, BJ
    Brockow, K
    Metcalfe, DD
    BLOOD, 2000, 96 (11) : 747A - 747A
  • [30] Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines
    van der Kuip, H
    Moehring, A
    Wohlbold, L
    Miething, C
    Duyster, J
    Aulitzky, WE
    LEUKEMIA RESEARCH, 2004, 28 (04) : 405 - 408
12345